AI Article Synopsis
Article Abstract
The accredited biomarker alpha-fetoprotein (AFP) offers limited sensitivity and specificity in the early detection of hepatocellular carcinoma (HCC). To improve the screening performance, des-gamma-carboxy prothrombin (DCP) has been identified as another promising biomarker of HCC, combined with AFP biomarkers. The results of the commercial optical enzyme-linked immunosorbent assay (ELISA) kit easily have the interference problem due to the optical methodology. The immunomagnetic reduction (IMR) assay based on the magnetic measurement was utilized to assay DCP biomarkers without the excellent antiinterference performances. A DCP magnetic reagent, composed of iron-oxide (Fe3O4 ) magnetic nanoparticles coated with anti-DCP antibodies solved in phosphoryl-buffer solution, was synthesized and characterized. In the test of standard DCP antigens, superior antiinterference and sensitivity than optical ELISA were proved. In the animal test, the results indicate good agreement between the IMR assay findings and the tumor sizes of HCC rats at all time points after the HCC implantation. The feasibility of the developed DCP magnetic reagent with the IMR for the detection of DCP is verified, and demonstrates the high potential for future clinical applications.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1109/TBME.2015.2478845 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Plasma extracellular vesicle neurofilament light chain as the biomarkers of the progression of Parkinson's disease.
Biomol Biomed
December 2024
Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan; Department of Neurology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Taipei Neuroscience Institute, Taipei Medical University, Taipei, Taiwan.
Parkinson's disease (PD) is a common neurodegenerative disorder characterized by progressive symptoms, underscoring the urgent need for predictive blood biomarkers. Plasma extracellular vesicles (EVs) offer a promising platform for biomarker development, with neurofilament light chain (NfL) emerging as a potential candidate for neurological diseases. This study evaluated plasma EV NfL as a biomarker for disease progression in a PD cohort.
View Article and Find Full Text PDFChanges in plasma biomarkers differentiate clinical stages of Alzheimer's disease using immunomagnetic reduction assays.
J Alzheimers Dis
November 2024
Dementia Center, Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
Background: Many groups have been using immunomagnetic reduction (IMR) for assaying plasma amyloid-β 1-40 (Aβ) peptide, Aβ peptide and total tau protein (T-Tau) in cognitively normal controls (NC), patients with amnestic mild cognitive impairment (aMCI) and Alzheimer's disease dementia (ADD). Tremendous results have been independently reported.
Objective: We used traditional knowledge databases (e.
Effect of mitochondrial oxidative stress on regulatory T cell manufacturing for clinical application in transplantation: Results from a pilot study.
Am J Transplant
November 2024
Department of Surgery - Transplant Division, College of Medicine, University of Kentucky, Lexington, Kentucky, USA; Lucille Parker Markey Cancer Center, University of Kentucky, College of Medicine, Lexington, Kentucky, USA; Alliance Research Initiative (TILT Alliance), University of Kentucky College of Medicine, Lexington, Kentucky, USA. Electronic address:
The manufacturing process of regulatory T (Treg) cells for clinical application begins with the positive selection of CD25 cells using superparamagnetic iron oxide nanoparticle (SPION)-conjugated anti-CD25 antibodies (spCD25) and immunomagnetic cell separation technology. Our findings revealed that the interaction of spCD25 with its cell target induced the internalization of the complex spCD25-interleukin-2 receptor. Accumulation of intracellular spCD25 triggered oxidative stress, causing delayed Treg expansion and temporary reduction in suppressor activity.
View Article and Find Full Text PDFBiomarker Assessment in Parkinson's Disease Dementia and Dementia with Lewy Bodies by the Immunomagnetic Reduction Assay and Clinical Measures.
J Alzheimers Dis Rep
October 2024
Department of Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA.
Background: Plasma biomarker assays provide an opportunity to reassess whether Alzheimer's disease, Parkinson's disease dementia (PDD), and dementia with Lewy bodies (DLB) plasma biomarkers are diagnostically useful.
Objective: We hypothesized that immunomagnetic reduction (IMR) of plasma biomarkers could differentiate between patients with PDD and DLB and healthy patients when combined with established clinical testing measures.
Methods: Plasma samples from 61 participants (12 PDD, 12 DLB, 37 controls) were analyzed using IMR to quantify amyloid-β 42 (Aβ), total tau (t-tau), phosphorylated tau at threonine 181 (p-tau181), and α-synuclein (α-syn).
Mediating role of obstructive sleep apnea in altering slow-wave activity and elevating Alzheimer's disease risk: Pilot study from a northern Taiwan cohort.
Sleep Health
October 2024
School of Respiratory Therapy, College of Medicine, Taipei Medical University, Taipei, Taiwan; Research Center of Artificial Intelligence in Medicine, Taipei Medical University, Taipei, Taiwan; Sleep Center, Taipei Medical University-Shuang Ho Hospital, New Taipei City, Taiwan; Division of Pulmonary Medicine, Department of Internal Medicine, Taipei Medical University-Shuang Ho Hospital, New Taipei City, Taiwan. Electronic address:
Article Synopsis
- Obstructive sleep apnea (OSA) might lead to changes in slow-wave sleep activity, which could increase the risk of developing Alzheimer's disease; this study aimed to explore the relationship between OSA symptoms and neurochemical biomarkers related to Alzheimer's.
- The study involved 42 individuals undergoing polysomnography to assess their sleep patterns and blood tests to measure levels of total tau (T-Tau) and amyloid beta-peptide 42 (Aβ), categorizing participants into low and high Alzheimer's risk groups.
- Results indicated that high-risk individuals had worse sleep metrics and unusual slow-wave sleep patterns, suggesting that OSA symptoms could indirectly raise levels of neurochemical markers linked to Alzheimer's, but further research is needed to establish direct causal links.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!